Suppr超能文献

进行性IgA肾病早期的类固醇治疗。一项10年随访研究。

Steroid therapy during the early stage of progressive IgA nephropathy. A 10-year follow-up study.

作者信息

Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S

机构信息

Department of Medicine, School of Medicine and Nursing, Kitasato University, Kanagawa, Japan.

出版信息

Nephron. 1996;72(2):237-42. doi: 10.1159/000188848.

Abstract

This study was undertaken to clarify the effect of corticosteroids on the long-term clinical course of the early stage of progressive IgA nephropathy. The early stage of progressive IgA nephropathy was defined as having moderate proteinuria between 1 and 2 g/day, creatinine clearance values of 70 ml/min or more, and a histological severity score of 7 or more. The number of patients who fulfilled these three conditions during 12 years from 1972 and then were continuously followed up for 10 years or more in our renal unit was 46. Twenty of them received steroid treatment for an average period of 18 months, and the remaining 26 patients had no steroid treatment. The initial data of proteinuria, creatinine clearance values, frequency of hypertensive cases, and histological scores of 7 or more were not different between the two groups: 1.4 +/- 0.4 vs. 1.3 +/- 0.3 g/day, 85 +/- 14 vs. 88 +/- 13 ml/min, 25 vs. 38%, and 10.7 +/- 2.5 vs. 11.0 +/- 3.0, respectively. During the follow-up period of 10 years, the renal survival rate was significantly different between the two groups (100 vs. 84% 5 years after starting therapy and 80 vs. 34% 10 years later; p < 0.001). The final creatinine clearance values were significantly different between the two groups (54 +/- 35 vs. 20 +/- 29 ml/min; p < 0.005). On the other hand, the patient groups with mild histological changes or decreased renal function due to moderate proteinuria showed no significant differences in the final outcome. These results indicate that corticosteroids are beneficial in stabilizing the renal function for a long time during the early stage of progressive IgA nephropathy, although this study was not a randomized one.

摘要

本研究旨在阐明皮质类固醇对进行性IgA肾病早期长期临床病程的影响。进行性IgA肾病的早期定义为:蛋白尿中度,每天1至2克,肌酐清除率值为70毫升/分钟或更高,组织学严重程度评分为7分或更高。1972年起的12年间符合这三个条件、随后在我们肾脏科持续随访10年或更长时间的患者有46例。其中20例接受了平均18个月的类固醇治疗,其余26例患者未接受类固醇治疗。两组间蛋白尿、肌酐清除率值、高血压病例频率以及组织学评分为7分或更高的初始数据无差异:分别为1.4±0.4与1.3±0.3克/天、85±14与88±13毫升/分钟、25%与38%、10.7±2.5与11.0±3.0。在10年的随访期内,两组间肾脏存活率有显著差异(治疗开始5年后为100%对84%,10年后为80%对34%;p<0.001)。两组间最终肌酐清除率值有显著差异(54±35与20±29毫升/分钟;p<0.005)。另一方面,组织学改变轻微或因中度蛋白尿导致肾功能下降的患者组在最终结果上无显著差异。这些结果表明,尽管本研究并非随机研究,但皮质类固醇在进行性IgA肾病早期对长期稳定肾功能有益。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验